Improving the Efficiency and Effectiveness of Genomic Science Translation Workshop Summary (2014) / Chapter Skim
Currently Skimming:
2 Connecting Basic Research and Health Care Needs
2 Connecting Basic Research and Health Care Needs
Pages 5-12
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 5... ...
• Speed, flexibility, teamwork, skilled management, and power ful technologies will likely be the hallmarks of the success of research in the future. Two speakers opened the workshop with broad overviews of the pathways from basic research to improvements in health care.
|
From page 6... ...
improving translation efficiency with a mission-oriented mindset: milestone- and outcome-focused research The costs of research and health care have risen, Liu said. Genomics, as a diagnostic tool, can be used as a systems optimizer, "where each diagnostic makes money by saving money for the system." Companies have begun to think about their business models in different ways to design cost-saving solutions to health problems.
|
From page 7... ...
With improved technology and the appropriate use of scaling and logistics, a single investigator can conduct much of the work, Liu said. In summary, Liu described that it took 41 years from the time of the genetic discovery in 1960 linking the Philadelphia chromosome as a marker for chronic myelogenous leukemia before imatinib (Gleevec)
|
From page 8... ...
GENOMICS and personalized cancer treatment Only some of what is called "basic research" is truly that, meaning that it is an interesting story but does not relate to a translational pathway, Huntsman said. True translational medicine requires that specific clinical questions and translational pathways be identified, but the current health care system is not prepared for the translational initiatives that Liu mentioned earlier, Huntsman said.
|
From page 9... ...
A mutation critical in the early development of ancer may no longer be active, or mutations that are invariably active c in one cancer type may no longer be active in another. One way to identify active mutations is to use existing bioinformatics tools to understand how mutations disrupt networks and then create lists of common and active mutations.
|
From page 10... ...
Medical analytics in a secure environment with honest brokers will be important not only to drive efficiency but also as a revenue generator for biotechnology companies. Such efforts will improve the effectiveness of delivery of health care by creating better outcomes at reduced costs.
|
From page 11... ...
The President's Council of Advisors on Science and Technology Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation would help provide a strategy for the coupling of transparency in data sharing with regulatory approval (PCAST, 2012)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.